Page 4 - Structural Protein News Today

In a recent study, published on the bioRxiv* preprint server, researchers identified human LRRC15 as an inhibitory receptor for SARS-CoV-2 entry, which directly binds to the receptor-binding domain (RBD) of the spike protein with a moderate affinity and inhibits spike-mediated entry.

Scientists utilize N. benthamiana for producing the N-protein and an antigenic cocktail containing the N-protein and SARS-CoV-2 S RBD.

Scientists explore the link between SARS-CoV-2 infection and anti-NMDAR encephalitis.

Phytochemicals are plant-derived molecules from medicinal plants that act as a prominent reservoir for treating a wide range of viral infections. In a new study, published in the journal Scientific Reports, scientists adopted a computational approach to identify Mpro inhibitors.

A new review aimed to describe the current state of knowledge on Sialodacryoadenitis virus, along with its characteristics and potential zoonotic threat.

A team of researchers studied the two main viroporins of SARS-CoV-2, namely Orf3a and Envelope (E) protein, from a structural viewpoint.

SARS-CoV-2 has a single-stranded RNA genome encoding both structural and non-structural proteins. Of these, the latter is known to play a variety of roles in viral replication and the assembly of new viral particles, as well as in suppressing cellular immune responses. A new study reports the activity of one such protein, the non-structural protein 14 (NSP14), which activates the inflammatory mediator NF-κB to trigger intense inflammation.

Screening for SARS-CoV-2 non-structural protein 14 inhibitors The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome generates 16 distinct non-structural proteins (nsp) that constitute the enzymes and accessory proteins responsible for virus replication once inside a host cell. These protein complexes produce and cap RNA strands that will go on to be translated by the host machinery. Capping the RNA in a manner that is recognized as similar to endogenous mRNA ensures compatibil...

Small molecule inhibitors of SARS-CoV-2 identified by screening Even as the vaccine rollout continues against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), seeking to bring an end to the coronavirus disease 2019 (COVID-19) pandemic, new variants emerge that show immune escape capabilities. Effective and safe drugs thus remain essential to treat severe infections with this virus. A new preprint, released on the bioRxiv* server, describes the identification of small molecule ...

Discovery of cryptic pocket in SARS-CoV-2 may lead to pan-coronavirus therapies Coronaviruses have been around for a long time and have caused several recent deadly outbreaks. The most recent is the ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A new research paper published in the Biophysical Journal describes a novel binding pocket used by a viral non-structural protein (nsp) to form an activated complex w...